Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Hematol Oncol Clin North Am. 2013 Aug;27(4):851-60, x. doi: 10.1016/j.hoc.2013.01.006.
B-cell receptor (BCR) signaling is essential for chronic lymphocytic leukemia (CLL) cell survival. Many kinases in the BCR signaling pathway are being studied as potential therapeutic targets. Ibrutinib (PCI-32765) is a novel first-in-class selective inhibitor of Bruton tyrosine kinase. Preclinical evidence suggests that ibrutinib inhibits CLL cell survival and proliferation and affects CLL cell migration and homing. Early clinical data in patients with CLL and non-Hodgkin lymphoma is encouraging. It is likely that ibrutinib and other drugs targeting the BCR pathway will become an integral component of CLL therapy.
B 细胞受体 (BCR) 信号转导对于慢性淋巴细胞白血病 (CLL) 细胞的存活至关重要。BCR 信号通路中的许多激酶正被研究作为潜在的治疗靶点。依鲁替尼（PCI-32765）是一种新型的首个布鲁顿酪氨酸激酶选择性抑制剂。临床前证据表明，依鲁替尼抑制 CLL 细胞的存活和增殖，并影响 CLL 细胞的迁移和归巢。在 CLL 和非霍奇金淋巴瘤患者中的早期临床数据令人鼓舞。依鲁替尼和其他靶向 BCR 通路的药物很可能成为 CLL 治疗的一个组成部分。
